Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
recombinant interferon alfa · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| recombinant interferon alfa | BIOLOGICAL | - |
| cytarabine | DRUG | - |
| imatinib mesylate | DRUG | - |
DISEASE CHARACTERISTICS: Cytogenetically proven Philadelphia chromosome positive chronic phase chronic myelogenous leukemia (CML) Initial diagnosis within the past 6 months No prior chemotherapy, including regimens used in peripheral blood progenitor cell (PBPC) mobilization for PBPC transplantation...
Top 20 of 63 competitors
Recombinant interferon alfa is used for the treatment of leukemia, specifically in the context of chronic myelogenous leukemia. It is being studied as a comparator in a clinical trial for patients with newly diagnosed chronic myelogenous leukemia. The drug is administered as part of an oncology treatment regimen.
Recombinant interferon alfa is developed by Novartis AG, a global healthcare company. Novartis is listed on the stock exchange under the ticker symbol NVS. The company is conducting clinical research on this drug for the treatment of leukemia.
Recombinant interferon alfa is in Phase 3 clinical development. It is being evaluated in a completed Phase 3 trial for patients with newly diagnosed chronic myelogenous leukemia. The drug is investigational and has not been approved by regulatory authorities based on the available data.
Recombinant interferon alfa is associated with one clinical trial, NCT00006343, which is a Phase 3 study titled 'STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia.' This trial has been completed and was conducted in the United States.
No, recombinant interferon alfa is not the same as STI571. In the clinical trial NCT00006343, STI571 is compared with recombinant interferon alfa plus cytarabine. STI571 is a separate drug being tested against the combination of recombinant interferon alfa and cytarabine in patients with newly diagnosed chronic myelogenous leukemia.